Identification of Noncovalent Small-Molecules from Virtual Screening Toward the Development of Potential KRAS Inhibitors.

Abstract excerpt

Kirsten rat sarcoma (KRAS) is an oncoprotein responsible for ∼ 20% of all human cancers. So far, only two covalent drugs are approved by the U.S. Food and Drug Administration (FDA) for the treatment of KRAS (G12C)-driven non-small cell lung cancer. However, their reliance on a covalent bond with cysteine at position 12 limits their effectiveness for treating other cancers driven by non-G12C KRAS mutations, and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Agents
• Share to Cell Line, Tumor